These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33622152)

  • 1. Hb S (
    Tsitsikas DA; Kamal M; Braimoh A; Benson S; Abukar J
    Hemoglobin; 2021 Nov; 45(6):355-357. PubMed ID: 33622152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
    Rutherford-Parker NJ; Campbell ST; Colby JM; Shajani-Yi Z
    Am J Clin Pathol; 2020 Oct; 154(5):627-634. PubMed ID: 32561909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
    Green ML; Savic RM; Tonda M; Jorga K; Washington CB
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):698-710. PubMed ID: 35447017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
    Hutchaleelaha A; Patel M; Washington C; Siu V; Allen E; Oksenberg D; Gretler DD; Mant T; Lehrer-Graiwer J
    Br J Clin Pharmacol; 2019 Jun; 85(6):1290-1302. PubMed ID: 30743314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of Voxelotor on quantitation of HbS levels by high-performance liquid chromatography in a patient with sickle cell disease.
    Giacomini L; Puricelli C; Sacchetti S; Zanotti V; Rolla R
    Int J Lab Hematol; 2023 Dec; 45(6):831-832. PubMed ID: 37604778
    [No Abstract]   [Full Text] [Related]  

  • 8. Voxelotor for the treatment of sickle cell disease.
    Vissa M; Vichinsky E
    Expert Rev Hematol; 2021 Mar; 14(3):253-262. PubMed ID: 33602029
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years.
    Estepp JH; Kalpatthi R; Woods G; Trompeter S; Liem RI; Sims K; Inati A; Inusa BPD; Campbell A; Piccone C; Abboud MR; Smith-Whitley K; Dixon S; Tonda M; Washington C; Griffin NM; Brown C
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29716. PubMed ID: 35451176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
    Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
    Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voxelotor: A Novel Treatment for Sickle Cell Disease.
    Herity LB; Vaughan DM; Rodriguez LR; Lowe DK
    Ann Pharmacother; 2021 Feb; 55(2):240-245. PubMed ID: 32674605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
    Rutherford NJ; Thoren KL; Shajani-Yi Z; Colby JM
    Clin Chim Acta; 2018 Jul; 482():57-59. PubMed ID: 29601794
    [No Abstract]   [Full Text] [Related]  

  • 13. Voxelotor for the treatment of sickle cell disease in pediatric patients.
    Brown C; Tonda M; Abboud MR
    Expert Rev Hematol; 2022 Jun; 15(6):485-492. PubMed ID: 35671094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
    Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
    Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A "Split" Hemoglobin S Peak.
    Colby JM; Shajani-Yi Z
    Clin Chem; 2020 Sep; 66(9):1250-1251. PubMed ID: 32870996
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of Voxelotor-hemoglobin complexes in the estimation of hemoglobin S levels by the current standard of care laboratory evaluation techniques.
    Alkindi S; Al Subhi A; Ali AEH; Pathare AV
    Front Med (Lausanne); 2023; 10():1149281. PubMed ID: 37153104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.
    Ferlis M; Lipato T; Roseff SD; Smith WR
    Eur J Haematol; 2022 Nov; 109(5):586-589. PubMed ID: 35848827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of voxelotor on hemoglobin electrophoretic and chromatographic profiles].
    Fellahi S; Mouri N; Giraud B; Martino S; de Luna G; Sakka M; Joly P; Bastard JP; Galacteros F; Moutereau S
    Ann Biol Clin (Paris); 2023 Jul; 81(3):320-326. PubMed ID: 37475172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world data on voxelotor to treat patients with sickle cell disease.
    Muschick K; Fuqua T; Stoker-Postier C; Anderson AR
    Eur J Haematol; 2022 Aug; 109(2):154-161. PubMed ID: 35460521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voxelotor for the Treatment of Sickle Cell Disease.
    Fantasia HC; Morse BL
    Nurs Womens Health; 2020 Jun; 24(3):233-237. PubMed ID: 32387142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.